A Study to Compare Fluticasone Propionate 100mcg/Salmeterol 50 mcg Inhalation Powder to Advair Discus 100/50

NCT03562923 | Unknown Phase 3 FDA Drug

• 1 other identifier: AI-FSX-001
• Study Type: interventional
• Target: 1,204
• Locations: 0 countries
• Sites: N/A

Brief Summary

To compare the efficacy and safety profiles of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder (test product) and ADVAIR DISKUS (fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder) (reference product) and to show that the efficacy of the 2 active products is superior to that of placebo in the treatment of subjects with asthma.

Conditions

Asthma

Outcome Measures

Primary Outcomes (2)

• Baseline-adjusted area under the serial FEV1-time curve

  Baseline-adjusted area under the serial FEV1-time curve calculated from time zero to 12 hours (AUC0-12h) on the first day of treatment.

  0-12 hours after dosing on day 1

• Baseline-adjusted, pre-dose FEV1

  Baseline-adjusted, pre-dose FEV1 on the last day of a 4-week treatment

  4-weeks

Study Arms (3)

Test Product

EXPERIMENTAL

Test Product, 100/50 mcg, 2 x daily

Drug: Test Product

Reference Product

ACTIVE COMPARATOR

Reference Product, 100/50 mcg, 2 x daily

Drug: Reference Product

Placebo

PLACEBO COMPARATOR

Placebo Product 2 x daily

Drug: Placebo

Interventions

Test Product DRUG

Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder

Test Product

Reference Product DRUG

ADVAIR DISKUS® 100/50 (Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder)

Also known as: ADVAIR DISKUS

Reference Product

Placebo DRUG

Placebo Product

Placebo

Eligibility Criteria

• Age: 12 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female subjects (≥ 12 years of age) of non-child bearing potential or of child bearing potential committing to consistent and correct use of an acceptable method of birth control.
• Diagnosed with asthma as defined by the National Asthma Education and Prevention Program (NAEPP) at least 12 weeks prior to screening.
• Pre-bronchodilator FEV1 of ≥40% and ≤85% of the predicted value during the screening visit and on the first day of treatment.
• Currently non-smoking; had not used tobacco products (i.e., cigarettes, cigars, pipe tobacco) within the past year, and had ≤ 10 pack-years of historical use.
• ≥15% reversibility of FEV1 within 30 minutes following 360 mcg of albuterol inhalation (pMDI).
• Able to discontinue their asthma medications (inhaled corticosteroids and long-acting β agonists) during the run-in period and for remainder of the study.
• Able to replace current short-acting β agonists (SABAs) with salbutamol/albuterol inhaler for use as needed for the duration of the study (subjects should be able to withhold all inhaled SABAs for at least 6 hours prior to lung function assessments on study visits).
• Able to continue the following medications without a significant adjustment of dosage, formulation, dosing interval for the duration of the study, and judged able by the investigator to withhold them for the specified minimum time intervals prior to each clinic visit:
• short-acting forms of theophylline 12 hours
• twice-a-day controlled-release forms of theophylline 24 hours
• once-a-day controlled-release forms of theophylline 36 hours
• Able to discontinue the following medications for the specified minimum time intervals prior to the run-in period and for the remainder of the study:
• oral corticosteroids 1 month
• parenteral corticosteroids 1 month
• oral short-acting β-agonists 12 hours

You may not qualify if:

• Life-threatening asthma, defined as a history of asthma episode(s) requiring intubation, and/or associated with hypercapnoea; respiratory arrest or hypoxic seizures, asthma related syncopal episode(s), or hospitalizations within the past year or during the run-in period.
• Evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that in the opinion of the investigator, would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbated during the study.
• Hypersensitivity to any sympathomimetic drug (e.g., salmeterol or albuterol) or any inhaled, intranasal, or systemic corticosteroid therapy.
• Medication(s) with the potential to affect the course of asthma or to interact with sympathomimetic amines, e.g.:
• β-blockers
• oral decongestants
• benzodiazepines
• digitalis
• phenothiazines
• polycyclic antidepressants
• Monoamine oxidase inhibitors
• Viral or bacterial, upper or lower respiratory tract infection or sinus or middle ear infection within 4 weeks prior to the screening visit or during the run-in period.
• Factors (e.g., infirmity, disability or geographic location) that the investigator felt would likely limit the patient's compliance with the study protocol or scheduled clinic visits.

Sponsors & Collaborators

• Amneal Ireland Limited: lead

MeSH Terms

Conditions

Asthma

Interventions

Fluticasone-Salmeterol Drug Combination

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Intervention Hierarchy (Ancestors)

Salmeterol Xinafoate; Albuterol; Ethanolamines; Amino Alcohols; Alcohols; Organic Chemicals; Amines; Phenethylamines; Ethylamines; Fluticasone; Androstadienes; Androstenes; Androstanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Drug Combinations; Pharmaceutical Preparations

Study Officials

• Irshad Haque

  Amneal Pharmaceuticals, LLC

  STUDY DIRECTOR

Central Study Contacts

Irshad Haque

CONTACT

631-952-0214; ihaque@amneal.com

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 25, 2018
• First Posted: June 20, 2018
• Study Start: October 1, 2018
• Primary Completion: May 1, 2019
• Study Completion: June 1, 2019
• Last Updated: June 20, 2018

Record last verified: 2018-06